A study of HFB200603 as a single agent and in combination with Tislelizumab in patients with advanced solid tumors

Status

Suspended

Phases

Phase 1

Study type

Interventional

Source

EU CTIS

Registry ID

CTIS2022-502891-22-00

Acronym

HFB-200603-01

Enrollment

Registered

2023-07-03

Start date

2023-08-02

Completion date

Unknown

Last updated

2025-09-09

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Advanced Solid Tumors

None listed

Sex/Gender

All

Age

18 Years to No maximum

Italy, Spain

None listed

Source: EU CTIS · Data processed: Feb 4, 2026